Evropska unija - litovščina - EMA (European Medicines Agency)

incline therapeutics europe ltd - fentanilio hidrochloridas - skausmas, po operacijos - analgetikai - ionsys skiriamas ūminio vidutinio sunkumo ir sunkiam pooperaciniam skausmui gydyti suaugusiems pacientams.

Evropska unija - litovščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprostas - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - mažinti (monoterapijai ar kaip papildoma terapija vartojant beta adrenoblokatorių) akispūdžiui lėtinės atviro kampo glaukoma, ir akies hipertenzijai.

Evropska unija - litovščina - EMA (European Medicines Agency)

pfizer limited - sunitinibas - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antinavikiniai vaistai - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

mylan pharmaceuticals limited - bimatoprostas/timololis - akių lašai (tirpalas) - 0,3 mg/5 mg/ml - timolol, combinations

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

bausch + lomb ireland limited - bimatoprostas/timololis - akių lašai (tirpalas) - 0,3 mg/5 mg/ml - timolol, combinations

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - bimatoprostas/timololis - akių lašai (tirpalas) - 0,3 mg/5 mg/ml - timolol, combinations

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - bimatoprostas - akių lašai (tirpalas) - 0,1 mg/ml; 0,3 mg/ml - bimatoprost

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - sunitinibas - kietosios kapsulės - 12,5 mg; 50 mg - sunitinib

Evropska unija - litovščina - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Litva - litovščina - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - sunitinibas - kietosios kapsulės - 12,5 mg - sunitinib